Deerfield Management Company, L.P. (Series C) Verve Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $124,358 - $206,611	11,504 New	11,504 $152,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $11.7 Million - $31.1 Million	750,000 New	750,000 $25.8 Million

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

Alphabet Inc. Mountain View, CA

12.3M
Shares

$59.9 Million
4.09% of portfolio
Black Rock Inc. New York, NY

6.62M
Shares

$32.1 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

4.96M
Shares

$24.1 Million
0.01% of portfolio
State Street Corp Boston, MA

4.25M
Shares

$20.6 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.01M
Shares

$19.4 Million
0.0% of portfolio

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $291M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account